Trial Profile

A Multi-Center, Open Label, Phase 1/2 Study of CP-383, in Patients With Advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CP 383 (Primary)
Indications Bladder cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Tasca Therapeutics

Most Recent Events

16 Sep 2025 According to Tasca Therapeutics media release, first patient in the trial has been dosed.
04 Sep 2025 Status changed from not yet recruiting to recruiting.
22 Jun 2025 Status changed from planning to not yet recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com